These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study. Meng X; Zeng Z; Wang Y; Guo S; Wang C; Wang B; Guo S Neuropsychiatr Dis Treat; 2022; 18():953-964. PubMed ID: 35535211 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053 [TBL] [Abstract][Full Text] [Related]
6. Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Afanasiev V; Demeret S; Bolgert F; Eymard B; Laforêt P; Benveniste O Neuromuscul Disord; 2017 Mar; 27(3):251-258. PubMed ID: 28082209 [TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of generalized myasthenia gravis in Hong Kong Chinese. Lee CY; Lam CL; Pang SY; Lau KK; Teo KC; Chang RS; Chan KH J Neuroimmunol; 2015 Dec; 289():177-81. PubMed ID: 26616888 [TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis. Inan B; Orhan IG; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E Ir J Med Sci; 2024 Aug; ():. PubMed ID: 39088160 [TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old. Doughty CT; Suh J; David WS; Amato AA; Guidon AC Muscle Nerve; 2021 Dec; 64(6):651-656. PubMed ID: 34378210 [TBL] [Abstract][Full Text] [Related]
14. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Roda RH; Doherty L; Corse AM Neuromuscul Disord; 2019 Jul; 29(7):554-561. PubMed ID: 31296355 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis. Ren J; Wang J; Liu R; Jin Y; Guo J; Yao Y; Luo J; Hao H; Gao F Eur Neurol; 2023; 86(6):387-394. PubMed ID: 37778340 [TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory myasthenia gravis by double-filtration plasmapheresis and rituximab: A case series of nine patients and literature review. Bennani HN; Lagrange E; Noble J; Malvezzi P; Motte L; Chevallier E; Rostaing L; Jouve T J Clin Apher; 2021 Jun; 36(3):348-363. PubMed ID: 33349954 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study. Lin J; Li Y; Gui M; Bu B; Li Z Ther Adv Neurol Disord; 2024; 17():17562864241251476. PubMed ID: 38751755 [TBL] [Abstract][Full Text] [Related]
18. The use of eculizumab in ventilator-dependent myasthenia gravis patients. Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175 [TBL] [Abstract][Full Text] [Related]
19. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977 [TBL] [Abstract][Full Text] [Related]
20. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis. Yang X; Zhang W; Chang X; Li Z; Du R; Guo J Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]